All patients received new drugs [immunomodulatory agents (IMIDs) or proteasome inhibitors (PIs)] in association with conventional chemotherapy as upfront treatment or incorporated into pre-transplant induction or post-transplant maintenance strategies, except for the patients enrolled in IFM 2005-01 trial who were randomized to vincristine-adriamicyn-dexamethasone (VAD) induction and VAD-dexamethasone-cyclophosfamide-etoposide-cisplatin before ASCT (
Vincristine
It is used in the treatment of a variety of cancers, including leukemia, lymphoma, and solid tumors.
Vincristine works by disrupting the mitotic spindle, leading to cell cycle arrest and apoptosis.
Effective use of vincristine requires careful dosing and monitoring to balance its therapeutic benefits and potential side effects, which can include neurotoxicity, myelosuppression, and constipation.
Researchers can leverage PubCompare.ai to optimize their vincristine research by identifying the most effective protocols and produts from the scientific literature, pre-prints, and patents - enhancing reproducibility and accuracy.
This AI-driven platform enables powerfull comparisons to uncover new insights and drive vincristine research forward.
Most cited protocols related to «Vincristine»
In LLPSDB, some protein annotations (mainly for natural proteins) such as localization, Gene Ontology (GO) term and sequences of some proteins (if not provided by the literature), were obtained from UniProt/NCBI. As IDRs and LCRs in proteins have been demonstrated to be generally critical in LLPS, the sequences of them are presented in visualization. IDRs were identified via searching MobiDB (28 (link)) or by PONDR VL3-BA algorithm (33 (link)) for those sequences not deposited in MobiDB, and only those segments with no fewer than 15 residues were taken into account (33 (link)). LCRs data were also from MobiDB or predicted by SEG algorithm (34 (link)) with default parameters. Additionally, in order to organize the data methodically, other information such as protein type (natural or designed), protein structure type (IDR, IDR-fold or Fold) and main components (whether DNAs or RNAs are included) were annotated. Other databases related with the corresponding protein, such as DisProt (27 (link)), OMIM (29 (link)), IDEAL (30 (link)), AmyPro (31 (link)), FuzzDB (32 (link)), as well as the PMID/DOI of the literature, were also linked from LLPSDB.
It is important to emphasize that LLPSDB focuses on situations where protein alone or with other components (proteins or nucleic acids) was validated to undergo LLPS (or NOT) in vitro. Since in many investigated systems, the mixtures of RNA such as total mRNAs (35 (link),36 (link)), instead of specific nucleic acid were added, the sequences of nucleic acid are not presented in LLPSDB. Those systems with only nucleic acids as main component (which means there is no protein) in solution were not included. In addition, systems with segregation of antibodies (such as IgG) and materials designed as drug carrier were also excluded. LLPSDB contains systems where the condensates were observed to flow, fuse, drop, wet and reverse (which were characterized as typical liquid-like droplets), or in which liquid morphology was identified by FRAP (fluorescence recovery after photobleaching), EM (electron microscopy) or other techniques. Systems in which assemblies change morphology from liquid in ripening, such as droplet-to-gel or droplet-to-aggregate were recorded in the database, but those form gels or aggregates directly from homogeneous solution were not deposited.
Most recents protocols related to «Vincristine»
Example 9
A pediatric patient with Stage IV Wilms tumor is treated with dactinomycin, doxorubicin, cyclophosphamide and vincristine for 65 weeks. Doses of the drugs are as follows: dactinomycin (15 mcg/kg/d [IV]), vincristine (1.5 mg/m 2 wk [IV)), Adriamycin (doxorubicin 20 mg/m2/d [IV]), and cyclophosphamide (10 mg/kg/d [IV]). Dactinomycin courses are given postoperatively and at 13, 26, 39, 52, and 65 weeks. Vincristine is given on days 1 and 8 of each Adriamycin course. Adriamycin is given for three daily doses at 6, 19, 32, 45, and 58 weeks. Cyclophosphamide is given for three daily doses during each Adriamycin and each dactinomycin course except the postoperative dactinomycin course. During each administration of dactinomycin and vincristine a dose of 0.2 cc/kg of DDFPe is administered while the patient breathes supplemental oxygen. *D'angio, Giulio J., et al. “Treatment of Wilms' tumor. Results of the third national Wilms' tumor study.” Cancer 64.2 (1989): 349-360.
Example 6
An adult patient with rhabomyosarcoma is treated with IV Vincristine at a dose of 1.4 mg/m2. Concomitantly the patient is administered 0.1 cc kg of DDFPc while breathing room air. Despite breathing room air, increased oxygen levels am still attained in the tumor tissue resulting in increased activity of the drug.
Patients received radiotherapy, chemotherapy, or chemoradiotherapy if they did not achieve lymphoma regression following first- and second-line HPI eradication therapy, or were at the localized stage without initial HPI, or had advanced-stage gastric MALT lymphoma. For radiotherapy, the clinical target volume included the entire stomach and regional lymph nodes and was prescribed as 30.6 Gy over 17 fractions on the stomach [20 (link)]. The internal target volume (ITV) and planning target volume were set using the motion information obtained from the 4-dimensional CT for assessment of breathing motions and defined as an expansion of 5 mm from the ITV considering the set-up error of the patient [20 (link)]. Patients with the involvement of ≥ 2 organs were excluded from radiotherapy. The R-CVP was the primary systemic chemotherapy regimen, consisting of rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, and vincristine 1.4 mg/m2 on day 1, and prednisolone 60 mg/m2 on days 1–5 every 21 days. Localized stage lesions involving small-sized mucosal layers in patients with initial HPI-negative findings could be selectively treated by endoscopic mucosal resection (EMR) and close observation. In the case of chemoradiotherapy, we only used additional radiotherapy for consolidation purposes after chemotherapy by the physicians’ decision. To investigate the side effects of each treatment modality, we reviewed the medical records following the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 5.0.
Top products related to «Vincristine»
More about "Vincristine"
This potent antineoplastic drug works by disrupting the mitotic spindle, leading to cell cycle arrest and apoptosis.
When used effectively, vincristine can provide significant therapeutic benefits, but it requires careful dosing and monitoring to balance its efficacy and potential side effects, such as neurotoxicity, myelosuppression, and constipation.
Researchers can leverage the power of PubCompare.ai, an AI-driven platform, to optimize their vincristine research.
This innovative tool enables them to identify the most effective protocols and products from the scientific literature, preprints, and patents, enhancing the reproducibility and accuracy of their studies.
By harnessing the power of AI-driven comparisons, researchers can uncover new insights and drive their vincristine research forward, exploring synergistic effects with other chemotherapeutic agents like paclitaxel, doxorubicin, cisplatin, and etoposide, as well as the use of adjuvants like DMSO and verapamil to improve drug delivery and efficacy.
Optimizing vincristine research is crucial for advancing cancer treatment and improving patient outcomes.
PubCompare.ai provides researchers with a powerful tool to navigate the vast array of scientific information, identify the most promising approaches, and ultimately, develop more effective and safer vincristine-based therapies.
Whether working with vincristine alone or in combination with other drugs, this AI-driven platform can be a game-changer in the field of oncology research.